Navigation Links
Reportlinker Adds R&D Trends: Osteoporosis - Strong pipeline bodes well for future treatment
Date:4/26/2011

NEW YORK, April 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

R&D Trends: Osteoporosis - Strong pipeline bodes well for future treatment

http://www.reportlinker.com/p0484932/RD-Trends-Osteoporosis---Strong-pipeline-bodes-well-for-future-treatment.html

Over the last 12 months, there have been encouraging developments in the osteoporosis pipeline, with new therapies either receiving regulatory approval or launching. Moreover, both in the clinical and preclinical pipeline, companies continue their quest to bring to market a new, safe, effective, and affordable anabolic drug to address unmet need in the osteoporosis market. Understand key dynamics in the R&D pipeline for new osteoporosis therapies Benchmark novel and existing therapies using the target product profile identified by DatamonitorSupport R&D decision making by evaluating osteoporosis clinical trial designs that have set a precedent, as well as analysis of discontinued projectsAccess Datamonitor's prediction of how the treatment landscape may change in the next 20 years The osteoporosis pipeline remains well stocked, with several products continuing their clinical trials and no significant discontinuations. There most exciting novel candidates with new mechanisms of action continue to be the new antiresorptives cathepsin K inhibitors and the anti-sclerostin monoclonal antibodies anabolics. The osteoporosis treatment paradigm has been largely static for the past 20 years, but this trend is likely to change as new drugs reach the market. It is probable that the fracture prevention strategy will evolve from just focusing on increasing bone mineral density to improving the bone quality and strength. The major change in the treatment of osteoporosis will be the launch of new efficacious and safe anabolic treatments, allowing physicians to use these treatments earlier in the algorithm and in a wider category of patients. In particular companies are targeting the Wnt pathway, bone morphogenetic proteins, and insulin-like growth factor. What are the key trends in the osteoporosis pipeline? What is the clinical gold standard and how do new candidates have to compare to this to successfully penetrate the market? How will new osteoporosis treatments evolve in the next 20 years? What are the requirements of European and US regulatory bodies to ensure approval of a novel candidate?

Executive Summary

Strategic scoping and focus

Datamonitor key findings

Related reports

OVERVIEW

Catalyst

Summary

CLINICAL PIPELINE OVERVIEW

Osteoporosis pipeline

The osteoporosis pipeline remains robust

Companies are focusing on developing anabolics as competition in the antiresorptive market increases

Mechanism of action

Late-stage development compounds recently discontinued

TARGET PRODUCT PROFILE

Comparator therapies

Fosamax (alendronate; Merck & Co)

Target product profile versus current level of attainment

CLINICAL TRIAL DESIGN IN OSTEOPOROSIS

Preclinical trials

Two different animal species tests are required by both the FDA and EMA

Preclinical trial design should reflect the clinical indication

Clinical trials

The FDA and EMA have different patient inclusion requirements for osteoporosis trials

Clinical endpoints

Future developments in clinical trial design

Trial endpoints unlikely to change

INNOVATIVE EARLY-STAGE APPROACHES

New targets for osteoporosis treatments

Targets for antiresorptive treatment

Targets for anabolic treatment

THE FUTURE OF TREATMENT OF OSTEOPOROSIS

Screening and osteoporosis diagnosis

Increased use of FRAX will lead to more osteoporosis prevention

Change in treatment outcomes

Focusing on bone quality

New treatment strategies

Anabolic treatments are likely to be used earlier in the treatment algorithm

Combination therapies

Personalized medicine

BIBLIOGRAPHY

Journal papers

Websites

APPENDIX

Contributing experts

Conferences attended

Report methodology

To order this report:

: R&D Trends: Osteoporosis - Strong pipeline bodes well for future treatment

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
5. Reportlinker Adds Nanomedicine Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanoporous Materials Report
8. Reportlinker Adds Membrane Bioreactors Report
9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):